Showing 1901-1910 of 5631 results for "".
- Valo Health Suspends Development of DR Drug Candidate After Phase 2 Study Resultshttps://modernod.com/news/valo-health-suspends-development-of-dr-drug-candidate-after-phase-2-study-results/2482594/Valo Health announced topline data from its phase 2 SPECTRA study of OPL-0401 in patients with diabetic retinopathy (DR). The study did not meet its primary or secondary endpoints based on the analysis in the prede&sh
- Signs of Glaucoma May Be Detectable Years in Advance of Disease Onsethttps://modernod.com/news/nih-signs-of-glaucoma-may-be-detectable-years-in-advance-of-disease-onset/2481989/Research funded by the National Eye Institute suggests that low density of pigment in the macula, the region of the retina required for sharp central vision, is associated with thinning of the retina and may serve as an early warning sign of glaucoma. The findings are based on nearly 400 women wh
- Two-Year Results for Aflibercept 8 mg from PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in DMEhttps://modernod.com/news/two-year-results-for-aflibercept-8-mg-from-photon-trial-demonstrate-durable-vision-gains-at-extended-dosing-intervals-in-dme/2481696/Regeneron released on Tuesday topline, 2-year (96 weeks) data for aflibercept 8 mg from the PHOTON trial in patients with diabetic macular edema (DME). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing intervals (after three initial monthly
- Evmann Creates Roadmap to Facilitate its Development into a €1 Billion Global Companyhttps://modernod.com/news/evmann-creates-roadmap-to-facilitate-its-development-into-a-eur1-billion-global-company/2480714/Dutch Evmann Investments Holding, the parent company of VSY Biotechnology, organized its 2022 Global Leadership Meeting last week in line with its strategic plans to become a "unicorn" company. "Unicorn" is a term used in the venture capital industry to describe 
- New 4-Year Data Show Genentech’s Enspryng Significantly Reduces Debilitating Relapses in People with NMOSDhttps://modernod.com/news/new-4-year-data-show-genentechs-enspryng-significantly-reduces-debilitating-relapses-in-people-with-neuromyelitis-optica-spectrum-disorder/2480350/Genentech announced new longer-term efficacy and safety data for Enspryng (satralizumab-mwge). The data show Enspryng has a favorable benefit-risk profile and is effective in reducing relapses over 4 years of treatment in people with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD, a
- Refractive Surgery Council Reports Strongest H1 Laser Vision Correction (LVC) Procedure Volume Growth in Nearly a Decadehttps://modernod.com/news/refractive-surgery-council-reports-strongest-h1-laser-vision-correction-lvc-procedure-volume-growth-in-nearly-a-decade/2479384/The Refractive Surgery Council (RSC) reported the strongest first half laser vision correction (LVC) procedure volume growth in nearly a decade. The 82 percent year-over-year growth, fueled by the strong quarter-over-quarter performance, resulted in 231,503 LASIK, SMILE and PRK procedures perform
- LION Eye Group to Develop New Retail Stores in New Yorkhttps://modernod.com/news/lion-eye-group-to-develop-new-retail-stores-in-new-york/2479074/New York-based LION Eye Group announced its intent to move forward with “LION Express,” a state-of-the art, eyewear focused, retail optometric store. The group is currently scouting locations in Garden City, Huntington,
- Market Scope: Refractive Surgery to Grow 9.6% a Year Through 2025, Despite COVID-19https://modernod.com/news/market-scope-refractive-surgery-to-grow-9-6-a-year-through-2025-despite-covid-19/2478774/Expanding use of products to treat refractive error will increase the role of devices and surgical procedures in the refractive landscape, according to a new Market Scope report. Globally, over 2.3 billion people require vision correction and have access to ophthalmic care. Global demand f
- Regeneron: Eylea Reduced Risk of Developing Vision-Threatening Events by 75% After 2 Years in Patients With DRhttps://modernod.com/news/regeneron-eylea-reduced-risk-of-developing-vision-threatening-events-by-75-after-two-years-in-patients-with-dr/2477283/Regeneron Pharmaceuticals announced positive 2-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection 2 mg (0.05 mL) in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR). The data were presented for the first time at the Angiogen
- Improved Premium IOLs Will Drive Growth in the Global IOL Market Over the Next 5 Yearshttps://modernod.com/news/improved-premium-iols-will-drive-growth-in-the-global-iol-market-over-the-next-5-years/2476449/Innovation in premium lens technology will fuel patient demand in the global IOL market over the next 5 years, according to a Market Scope report. The improved technology will provide better visu